國辦印發深化醫改重點任務推進國家組織藥品集中採購和使用試點
據《新華社》報道,國務院辦公廳印發《深化醫藥衛生體制改革2019年重點工作任務》,《任務》明確了兩方面重點工作內容。
一是要研究制定的文件,主要涉及健康中國行動、促進社會辦醫健康規範發展、鼓勵仿製的藥品目錄、規範醫用耗材使用、以藥品集中採購和使用為突破口進一步深化醫改、醫療機構用藥管理、互聯網診療收費和醫保支付、衛生專業技術人員職稱制度改革、建立完善老年健康服務體系、二級及以下公立醫療機構績效考核、加強醫生隊伍管理、醫聯體管理、公立醫院薪酬制度改革、改進職工醫保個人賬戶、醫療保障基金使用監管等方面的15個文件。
二是要推動落實的重點工作,主要圍繞解決看病難、看病貴問題和加強醫院管理等方面,提出21項具體工作。解決看病難方面,提出推進國家醫學中心和區域醫療中心建設、有序發展醫聯體促進分級診療、深化「放管服」改革支持社會辦醫、促進「互聯網+醫療健康」發展、統籌推進縣域綜合醫改、實施健康中國行動、加強癌症等重大疾病防治等重點工作。
解決看病貴方面,提出推進國家組織藥品集中採購和使用試點、推進高值醫用耗材改革、鞏固完善國家基本藥物制度、推進醫保支付方式改革、完善公立醫院補償機制、深化公立醫院綜合改革、深入實施健康扶貧等重點工作。加強醫院管理方面,提出開展公立醫院績效考核、進一步改善醫療服務等重點工作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.